康泰生物上半年净利同比降逾七成

Core Insights - The company reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The net profit attributable to shareholders was 37.53 million yuan, showing a significant decline of 77.3% compared to the previous year [1] Company Overview - The company, 康泰生物, specializes in the research, production, and sales of human vaccines [1] - Key products currently marketed include the 13-valent pneumococcal polysaccharide conjugate vaccine, acellular DTP-Hib combination vaccine, freeze-dried human rabies vaccine, 23-valent pneumococcal polysaccharide vaccine, recombinant hepatitis B vaccine, Hib conjugate vaccine, adsorbed acellular DTP combination vaccine, and live attenuated varicella vaccine [1]